Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04667403 | Telemedicine in the Management of Pain in Patients With Advanced or Metastatic Pancreatic Cancer(PANTELO) | unknown | N/A | 50 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT02794337 | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer(TACE-SBRT) | unknown | Phase 2 / Phase 3 | 67 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 27, 2022 |
| clinicaltrials |
| NCT04033432 | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 14 | Northwestern UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05339581 | IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation(iPLENTY-pvtt) | unknown | N/A | 78 | RenJi HospitalOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT04605575 | Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 | 208 | Sun Yat-sen UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346107 | PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer | unknown | Phase 2 | 100 | Xijing HospitalOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346861 | Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab | unknown | Phase 3 | 240 | Fudan UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT02849535 | Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer(PRISM care) | unknown | N/A | 190 | Hospices Civils de LyonOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05340543 | Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV)(DERMOCTAV) | unknown | — | 150 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05342389 | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 68 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT04213404 | Ribociclib and Spartalizumab in R/M HNSCC(RISE-HN) | unknown | Phase 1 | 13 | National Taiwan University HospitalOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT03251313 | PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients | unknown | Phase 1 | 31 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04192903 | Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer | unknown | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04609215 | ImmunoBreast - A Phase Ib Study | unknown | Phase 1 / Phase 2 | 20 | Henrik DitzelOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04634747 | Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer | unknown | Phase 2 | 53 | OncoPep, Inc.INDUSTRY | 0 | Apr 20, 2022 | clinicaltrials |
| NCT04745975 | Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04848597 | PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP | unknown | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05334810 | DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer | unknown | Phase 2 | 191 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 19, 2022 | clinicaltrials |
| NCT03711305 | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | unknown | Phase 3 | 462 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2022 | clinicaltrials |
| NCT04457700 | CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC | unknown | — | 218 | Peking UniversityOTHER | 1 | Apr 18, 2022 | clinicaltrials |
| NCT04675866 | Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer | unknown | N/A | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05319392 | Transcriptomic Signatures in Gastric Adenocarcinoma(GAC) | unknown | — | 48 | Sanjay Gandhi Postgraduate Institute of Medical SciencesOTHER_GOV | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05171439 | Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples | unknown | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05315830 | A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric | unknown | Phase 1 | 10 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT02759900 | Using a Cold Atmospheric Plasma Device to Treat Skin Disorders | unknown | N/A | 100 | The Skin Center Dermatology GroupINDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT05320458 | Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer | unknown | N/A | 11 | Hasan Kalyoncu UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05321329 | Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients(ACAPP) | unknown | Phase 2 | 28 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05322499 | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | unknown | Phase 2 | 80 | Zhejiang Cancer HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05317325 | A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT01441349 | Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | unknown | Phase 2 | 192 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05313906 | RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04602702 | Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors(PDXovo) | unknown | — | 50 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT04664582 | Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck | unknown | N/A | 100 | Jewish General HospitalOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05024539 | Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma | unknown | — | 300 | Shujun YangOTHER_GOV | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05311189 | Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 5, 2022 | clinicaltrials |
| NCT05311319 | HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05293327 | IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate(IMP3PCNA) | unknown | — | 70 | Sohag UniversityOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT04943679 | Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC | unknown | — | 15 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05200221 | A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice | unknown | — | 300 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03799744 | Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 | 20 | Institut Català d'OncologiaOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05299203 | BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma) | unknown | Phase 1 | 18 | West China HospitalOTHER | 0 | Mar 28, 2022 | clinicaltrials |
| NCT05299255 | Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05205629 | A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC | unknown | — | 150 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT05291663 | Effect of Accelerated RTH in Squamous Cell Carcinoma in Head and Neck | unknown | — | 100 | Assiut UniversityOTHER | 0 | Mar 23, 2022 | clinicaltrials |
| NCT05288127 | Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature | unknown | Phase 2 | 55 | University of MalayaOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT05289336 | DAHANCA 27 Transoral Laser Microsurgery for T1a Glottic Cancer(DAHANCA 27) | unknown | Phase 2 | 80 | Danish Head and Neck Cancer GroupNETWORK | 1 | Mar 21, 2022 | clinicaltrials |
| NCT05286099 | The Surveillance of Hepatocellular Carcinoma | unknown | — | 100 | Chinese PLA General HospitalOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05287880 | Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC | unknown | — | 60 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Mar 18, 2022 | clinicaltrials |
| NCT05281926 | A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients | unknown | Phase 1 | 10 | National Taiwan University HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Apr 28, 2022source: clinicaltrials